News

Researchers have identified risk factors that may predispose children to more severe initial angioedema attacks — factors such as male gender, preschool age, presence of fever or hives, and a history of allergies. Epinephrine treatment and receiving care in a pediatric observation unit, on the other hand, were factors that…

Researchers developed a questionnaire, called the Angioedema Control Test (AECT), that may be helpful in monitoring disease control and patient-reported outcomes among people with recurrent angioedema. The tool is described in the journal Allergy, in the study, “Development of the Angioedema Control Test (AECT) – A Patient…

The lack of control of a key enzyme associated with the overproduction of bradykinin seems to be the common root cause of all forms of hereditary angioedema with normal C1-inhibitor activity, a study reports. The study, “Impaired control of the contact system in hereditary angioedema with…

A Thai version of the Angioedema Quality of Life (AE-QoL) questionnaire is a reliable way to measure health-related quality of life in Asian people with recurrent angioedema, a new study demonstrates. The study, “Angioedema quality of life questionnaire (AE-QoL) – interpretability and sensitivity to change,” was published…

Angioedema News brought you daily coverage of important discoveries, treatment developments, clinical trials, and other important events dealing with angioedema throughout 2019. As a reminder of what mattered most to our readers in 2019, here are the 10 most-read articles of last year, with a brief description of…

KVD001 safely protects people with diabetic macular edema from losing their vision, according to a Phase 2 trial conducted by the treatment’s developer, KalVista Pharmaceuticals. DME is a form of angioedema that is caused by the leaking of blood vessels which lead to fluid accumulating in the…

BioCryst Pharmaceuticals has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) requesting the approval of  berotralstat (BCX7353), a once daily, oral treatment to prevent swelling attacks in people with hereditary angioedema (HAE). The latest results of APeX-S and APeX-2…

With so much recent publicity surrounding gene therapy, it’s no surprise that the topic was a major focus of the recent 2019 NORD Rare Diseases & Orphan Products Breakthrough Summit. From diagnosis and clinical trial design to manufacturing, pricing strategies, and ethical concerns, gene therapy — both its high…

Factors involved in blood vessel permeability — called VEGF-A, VEGF-C, and sPLA2 — may predispose people who take ACE inhibitor medications for high blood pressure to develop non-allergic angioedema, a study reports. Moreover, the findings indicate that switching to sartans, another class of antihypertensive medicines,…

Despite skyrocketing healthcare costs, President Trump is committed to protecting the 30 million or so Americans with rare diseases and ensuring timely, affordable access to lifesaving treatments, the nation’s highest-ranking health official said. “We have to think about how our financing system can protect those with serious and rare illnesses.